Posted on

Silo Wellness Brings Marley One Mushrooms to the U.K. Market through Distribution Agreement with LocoSoco Limited

Silo Wellness Brings Marley One Mushrooms to the U.K. Market through Distribution Agreement with LocoSoco Limited

TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or the “Company”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, today announced a nationwide distribution partnership with Essex-based U.K. brand distributor LocoSoco Group Plc (“LocoSoco”) (DIMA: AV), pursuant to a distribution agreement dated August 4, 2021 (the “Distribution Agreement”). The Distribution Agreement stipulates LocoSoco as the exclusive U.K. distributor for Silo Wellness’ full portfolio of Marley One branded mushroom products.

This partnership announcement comes on the heels of Silo Wellness’ launch of Marley One, the first global functional and psychedelic mushroom consumer brand, created in collaboration with the family of legendary musician Bob Marley. The Distribution Agreement cements a solid route to market for Marley One products that can keep pace with consumer demand across the region. Silo Wellness is also the first global psychedelics company to access the nationwide network of a large-scale distributor to reach consumers across the U.K. at mainstream retail stores.

“Since the launch of Marley One, we’ve been vetting potential partners to help us bring the powerful health and wellness benefits of functional mushrooms to the U.K., where consumer interest in these products is on the rise, and psychedelic products as regulations allows,” said Douglas K. Gordon, Chief Executive Officer, Silo Wellness. “In LocoSoco, we’ve found a uniquely structured distribution network and like-minded collaborator who shares not only our dynamic vision for the mushroom category but also our principles around community building and value sharing at every point in the supply chain. We think the industry at large will benefit from the synergies of these two established, publicly-traded companies working in sync.”

LocoSoco will distribute the full line of Marley One mushroom products, beginning with the brand’s initial five functional mushroom tinctures, to independent retailers, buying groups, health food stores, online retailers and influencers and their e-commerce affiliates, across the United Kingdom. The exclusive distribution by LocoSoco is based on a minimum commitment of orders with a value of US $1.4M of Marley One products. The Agreement reflects consumer demand for mushroom-based wellness products and the market potential for functional mushrooms in particular, which constituted a GBP £18,409 million, or US$25,415 million market globally, in 2020, according to Mordor Intelligence. The global psychedelic drugs market at large is projected to reach US$6.85 billion by 2027, growing at a CAGR of 16.3% over the next eight years, according to Data Bridge Market Research.

The initial portfolio of Marley One mushroom products is a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica. Marley One mushroom tinctures include species such as cordyceps, lion’s mane, chaga, reishi and turkey tail that offer a range of distinct health and wellness benefits, from improved immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics. LocoSoco will be the sole distributor of Marley products across the U.K.

“We are thrilled to align with Silo Wellness, a company catalyzing growth in the burgeoning functional mushroom industry, to build a strategic route to market for their iconic Marley One product portfolio,” said James Perry, Founder and Chief Executive Officer of LocoSoco. “We are extremely selective with who we choose to partner with, and we’re proud to leverage our unique network of local and independent retailers to support a future-thinking, sustainable and ethical brand like Marley One in gaining access to consumers and communities across the U.K.”

For more information about Silo Wellness, please visit https://www.silowellness.com/. To buy Marley One products outside of the U.K., please visit https://marleyone.com/ and visit https://locoso.co/marley-one for U.K. sales.

ABOUT SILO WELLNESS
Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly-traded company on the Canadian (CSE: SILO) and Frankfurt (FRA: CK70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.marley.one.

For more information about Silo Wellness, please visit www.silowellness.com.

For further information, please contact:

Silo Wellness Media Relations:
hello@trailblaze.co

Silo Wellness Investor Relations:
(778) 383-6740
ir@silowellness.com

ABOUT LOCOSOCO GROUP PLC

LocoSoco builds technology to profit from creating sustainable communities. We work with community partners to turn community assets into eco-enterprises enabling them to generate additional revenues whilst supporting the transition to sustainable alternatives.

Community partners have the opportunity to engage with their local community on sustainability, whilst also earning additional revenue for themselves, their businesses and causes.
LocoSoco Group Plc listed on the Austrian Wiener Borse Direkt Market in February 2019.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Distribution Agreement, the distribution partnership with LocoSoco and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Delic Announces Ifetayo Harvey–Drug Reform Advocate and Founder and Board President of the People of Color Psychedelic Collective– to Speak at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, a never been seen before, two-day immersive Edutainment experience for revolutionary thought, health & wellness and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, August 4, 2021 – Delic Holdings Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that

Ifetayo Harvey will serve as one of the event’s mainstage speakers. Meet Delic is the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Harvey is the Founder and Board President of the People of Color Psychedelic Collective, long-time advocate for promoting drug policies grounded in science, compassion, and human rights, as well as the Social Media Manager for Caring Across Generations, an organization which creates a new way to live well and age with dignity in America.

Harvey states, “I am excited to push the boundaries of how we talk and think about wellness in our society at Meet Delic. I want our society to truly value and create wellness for everyone.” During her tenure at The Drug Policy Alliance, which is the nation’s leading organization advocating to end the war on drugs, Harvey fought hard for people to no longer be punished for what they put in their bodies. This created a deep desire within Harvey to further champion that  individuals be given the sovereign right and choice to use alternative medicines such as psychedelics without fear and impunity.

The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

“It is an honor to have Ifetayo Harvey speak at our conference and bring her unique perspectives on health, life and culture to our attendees,” said Delic co-founder, Jackee Stang. “She is a powerful voice in the movement toward embracing psychedelic wellness and reform and her work to right many wrongs in the ‘war on drugs’ is remarkable.”

The twenty hours of panels and keynotes will include a broad array of topics such as: “How Psychedelics Can be Effectively Used for Physical Optimization,” “PTSD Reset and Recovery,” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” microdosing, activism, sexuality, and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

HAVN LIFE HARVESTS FIRST CROP OF PSILOCYBIN MUSHROOMS AT ITS JAMAICA FACILITY

HAVN Life will export to Delic Labs in Canada for quality control and testing. This makes HAVN Life the first in the Caribbean Community and Common Market to export psilocybin.

Vancouver, BC – HAVN Life Sciences Inc. (CSE : HAVN) (FRA: 5NP) (FSE: 5NP)  (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is proud to announce the harvest of its first crop of psilocybin-containing mushrooms from their growing and production facility in Jamaica.

Working with its partner, GMP manufacturer P.A. Benjamin in Kingston, the Company will export the harvested psilocybin to Canada where it will be tested for safety and quality control through its lab partner, Delic Labs.

“This is the moment we have been tirelessly working towards,” says HAVN Life CEO, Tim Moore. “We’ve been aggressively meeting the targets in our strategic roadmap and having this last piece in place with DELIC Labs will enable HAVN Life to become the first and top choice for product supply globally,“ he adds.

Founded by award-winning chemist, Dr. Markus Roggen, and University of British Columbia Professor, Dr. Glenn Sammis, Delic Labs is a federally-authorized psilocybin and cannabis research laboratory—one of a handful of licensed psilocybin research labs in Canada. Delic Labs is one of the leading facilities in the world focused on QA/QC and safety testing for psilocybin and other psychedelic compounds. HAVN Life’s partnership with Delic Labs will facilitate the supply of product to the Company’s research and clinical partners, marking a very important step in HAVN Life’s strategy to produce quality-controlled, standardized product for research and clinical trials in North America, the Caribbean Community and Common Market (CARICOM) and Europe.

“Delic Labs is delighted to partner with HAVN on some of the world’s first psilocybin mushroom testing. Our lab has significantly built out its analytical and research capabilities to offer quality and safety testing to the psychedelic industry.” says Dr. Markus Roggen. “Psilocybin mushrooms are exciting and challenging botanicals with major medical potential. We are honored to have HAVN’s trust as their quality and safety testing partner in such a ground-breaking new industry.”

With this first harvest, HAVN Life will be able to begin supplying product to partners around the world, establishing the Company as an early mover in the ability to supply companies with high-quality, naturally derived psilocybin as markets open up around the globe.

“Having been in Jamaica since March setting up the HAVN Labs facility, this first harvest feels celebratory after an intense period of work,” says Dr. Ivan Casselman, Chief Psychedelic Officer at HAVN Life. “We are now very focused on delivering product to our supply partners and developing our own APIs going forward,” he adds.

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter,  Instagram and Youtube.

About Delic Labs

Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.

Connect

Investor Relations
ir@havnlife.com
(604) 687-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife

Media Contact
savi@emergence-creative.com
(647) 896-8078

 

LinkedInFacebookTwitterEmailShare
Posted on

Red Light Holland Signs Definitive Agreement with Mera Life Sciences and Files Annual Financial Statements

Toronto, Ontario–(Newsfile Corp. – July 30, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles, is pleased to announce that its financial results for the year ended March 31, 2021 (“FY21”) have been filed on SEDAR. Separately, the Company has entered into a definitive agreement as part of completing its previously announced acquisition of Mera Life Sciences (“Mera”).

Financial Statements

The Company is pleased to announce that its annual financial statements for the year ended March 31, 2021 are now available on SEDAR and highlights key data points below:

– Q4 FY21 revenue grew 535% over Q3 FY21

– During FY21, the Company realized approximately $1.3 million gain on the sale of marketable securities

– As SR Wholesale was acquired on March 19, 2021, a limited portion of SR Wholesale’s revenue could be attributed to the Company’s financial results for FY21

– Since being acquired, SR Wholesale has generated $700,000+ of revenue on an unaudited basis, a substantial portion of which is expected to be recognized on the Company’s Q2 FY22 financial results, alongside larger volumes of truffles from the second batch

– Product from the Company’s second, 1,000,000-gram harvest, was not available until after this reporting period and thus is not reflected on the Company’s FY21 results

Mera Life Sciences

The Company has also entered into a definitive agreement (the “Acquisition Agreement“), dated July 29, 2021, pursuant to which Red Light Holland will acquire 100% of the issued and outstanding shares of Mera for $2,450,000. The consideration is comprised of up to 7,000,000 common shares of the Company (the “Red Light Shares”), based on a price per Red Light Share of $0.35. The transaction is subject to several closing conditions, however the Company expects closing to take place during the first week of August, 2021. Mera is a pioneer licensee in St. Vincent and the Grenadines (“SVG”) that has spent the last 17 months working with government agencies and scientists to develop a Modern Medicinal Wellness Industry in the country.

The Red Light Shares will be released to the vendors based on the achievement of several milestones, which include: the importation of iMicrodose truffles to SVG; the approval of the transfer of the license by the government from Mera to Scarlette Lillie Sciences and Innovation; the successful prescription and sale of iMicrodose truffles to at least five patients in SVG or the successful administration of iMicrodose truffles to at least five participants in a scientific treatment study in SVG; the chemical extraction and testing of the iMicrodose truffles; the successful export of iMicrodose truffles from SVG to another jurisdiction in conformity with all national and international laws applicable to the State of St. Vincent and the Grenadines; and the final implementation of SVG’s regulatory framework for the psychedelics industry.

Mera currently holds a Medicinal Industry Development License (the “License“) issued by the SVG Bureau of Standards, which permits the research, cultivation, production, development and extraction, import and export, clinical treatment facilities, and prescribed patient access in specifically licensed clinical treatment facilities for medicinal purposes and scientific research only. The License applies to the following compounds: Turmeric, Aloe Vera, Papaya, Arrowroot, Soursop, Coconut, Ginger, Moringa, Ayahuasca, Mushroom, Iboga, Sassafras, Peyote, Psilocybin, Ibogaine, Dimethyltryptamine (DMT), Mescaline, Ketamine, 3-4 Methylenedioxy – Methamphetamine (MDMA), Lysergic Acid Diethylamide (LSD), 5-Methoxy-N,N-Dimethyltrypotomine (5-MeO-DMT). The Company has worked closely with the Ministry of Agriculture and Industry, The Bureau of Standards, Dr. Jean Saville-Cummings, molecular biologist and Professor Leonard O’Garro, Executive Director Annette Mark at Invest SVG, and the SVG government to assist in the development of the final regulatory framework which will govern the Company’s expected activities in SVG. The Company has been informed by the government of SVG that it anticipates all these regulations for the psychedelics industry (current draft in substantially final form at the Office of the Attorney General) to be made law in the near future.

“This is another fantastic milestone for our company,” said Todd Shapiro, CEO and Director of Red Light Holland. “Over the last year, we have put extensive work into laying the foundation to be the true global leader in the push to provide immediate commercial access to psychedelic substances for those in need. Our objective is to consistently demonstrate quarter on quarter revenue growth, which we did this quarter, and which we expect to materially increase into our next quarter. We are also laser focused on achieving this growth while carefully managing our operating expenses, and the fact that our cash position remains very strong indicates our success in doing so. We’ve also made great investments which have paid off meaningfully!”

“In closing the acquisition of Mera, we’ve also executed on two other major initiatives; accessing new markets where possible and finalizing the addition of applied sciences capabilities to our business,” added Shapiro. Having spent a significant amount of time working with the major stakeholders in St. Vincent and the Grenadines over the last six months, I am confident that this acquisition will allow us to broaden our scope for research and development, production and patient access of psychedelic compounds in groundbreaking ways. We are proud of being international pioneers and our quest to expand into progressive and emerging psychedelic markets in various countries, in my opinion, has just begun.”

Change of Auditors

The Company has changed its auditor from McGovern Hurley LLP (the “Former Auditor“) to MNP LLP (the “Successor Auditor“). The Former Auditor resigned amicably effective March 1, 2021 after the Company’s formation of Red Light Oregon. The Company’s board of directors appointed the Successor Auditor, to fill the resulting vacancy, until the close of the next annual meeting of the Company’s shareholders. The change of auditor notice required under National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102“) and associated materials are filed on SEDAR under the Company’s profile. There were no reservations or modified opinions in any auditor’s reports nor any reportable events as defined in NI 51-102 in connection with the audits by the Former Auditor of the Company’s most recently completed financial year or any subsequent period.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include but are not limited to: the Company’s ability to complete the acquisition of Mera; the anticipated continued growth of the Company; the ability of the Company to explore further psychedelic products; the passing of legislation and regulations favourable to the Company by the government of St. Vincent and the Grenadines; and the ability of the Company to further develop operations in St. Vincent and the Grenadines.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to obtain shareholder approval Acquisition Agreement; the Company’s ability to continue as a going concern; the continued commercial viability and growth in popularity of functional mushrooms and/or magic truffles; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; the continued development of functional mushroom and magic truffle growth technology; the continued growth of the Company; the Company’s ability to obtain regulatory approval of its Acquisition Agreement; and the ability of the Company complete the acquisition of Mera.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the risks associated with the psychedelics industry in general such as operational risks in growing, competition, incorrect assessment of the value and potential benefits of various transactions; failure to obtain required regulatory and other approvals, in particular with respect to completing its acquisition of Mera; risk that the Company’s planned acquisition of Mera will not result in growth for the Company; risk that the government of St. Vincent and the Grenadines will not pass regulations and/or legislation which is favourable for the Company; risks associated with conducting business with St. Vincent and the Grenadines; expectations regarding future investment, growth and expansion of the operations of the businesses; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the cannabis and magic psychedelics industries, including the global regulatory landscape and enforcement related to cannabis and psychedelics, political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis and psychedelics industries; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Red Light Holland disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Delic Announces Aubrey Marcus, New York Times Best Selling Author and Founder/CEO of ONNIT to speak at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, a first-of-its-kind, immersive Edutainment experience for revolutionary thought, holistic and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, July 29, 2021 – Delic Holdings Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Aubrey Marcus will serve as one of the headline speakers at Meet Delic the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Marcus is the holistic health founder and former CEO of ONNIT, a New York Times Best-selling author of Own the Day, Own Your Life, host of the Aubrey Marcus podcast, which boasts over 50 million downloads on iTunes, as well as the founding member of Fit for Service, one of the world’s most vital transformational communities.

As a lifelong advocate of holistic health, Aubrey is most passionate about raising awareness for the benefits of psychedelic medicine. “Psychedelic medicines have been an inexorable part of my story for the last 22 years. I’m looking forward to sharing more of my story with everyone at the Meet Delic event,” stated Marcus.

The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

“It is an honor to have Aubrey Marcus speak at our conference and bring his unique perspectives on health, life and culture to our attendees,” said Delic co-founder, Jackee Stang. “He is an experienced psychonaut, successful entrepreneur and a true renaissance man and his presence at the event will be invaluable.”

Panels and keynotes will include a broad array of topics such as: “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “PTSD Reset and Recovery,” “How Psychedelics Can be Effectively Used for Physical Optimization,” microdosing, activism, sexuality, and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About DELIC Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of DELIC’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, DELIC is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of DELIC to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, DELIC has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although DELIC believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and DELIC does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology

VANCOUVER, BC, July 29, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal third quarter results ended May 31, 2021.

In the third quarter, Numinus maintained a healthy cash position, achieved key milestones in its lab and proprietary portfolio, expanded the clinic network, and continued to advance its basic and clinical research.

All financial results are reported in Canadian dollars unless otherwise stated.

Q3 2021 Highlights:

  • Cash balance of $63.2 million as at May 31, 2021.
  • Completed $40.3 million bought deal financing and exercised $1.6 million in warrants and options.
  • Generated revenues of $562,076 and $1,022,771 for the three and nine months, respectively, ended May 31, 2021, compared to $216,244 and $610,148 for the same periods, respectively, ended May 31, 2020, for a total year-over-year increase of 160% and 68%, respectively.
  • Received amendments to the Health Canada licence under Numinus Bioscience, including the addition of Ketamine and LSD to the list of permitted research substances (alongside DMT, MDMA, Mescaline, Psilocin, Psilocybin) and expanded ability to produce finished products for research and supply of other groups. These changes expand the lab’s capabilities and position as an industry manufacturer and supplier.
  • Announced 7,500 square foot expansion of Numinus Bioscience’s research laboratory.
  • Announced a Phase 1 clinical trial to assess the safety and efficacy of a Psilocybe extract developed at Numinus Bioscience.
  • Announced key milestones in the compassionate access trial of psilocybin-assisted psychotherapy for substance use disorders.
  • Made key leadership hires in business development and strategy, clinic operations, communications and marketing, experience design, lab operations and M&A to support growth and innovation.

Highlights Subsequent to Quarter End:

  • Announced acquisition of the Neurology Center of Toronto (NCT) for a total of $1.1 million, allowing for the planned expansion of NCT into a comprehensive neurologic care centre specialized in psychedelic neurology.
  • Filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a rapid production process containing psychoactive compounds, with the first proprietary extract from Psilocybe cubensis containing psilocybin, other indole alkaloids and additional beneficial compounds.
  • Received Health Canada approval for the compassionate access trial of MDMA-assisted therapy in collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS).
  • Uplisted to Tier 1 of the TSX Venture Exchange.

Commentary and Outlook

“Q3 underscores that Numinus is well into its next phase of rapid growth. Continuing the strong performance seen in Q2, we’ve maintained a healthy cash balance while making key investments in our human and technical infrastructure that provide a strong foundation for the significant advances seen across our lab and clinics,” said Payton Nyquvest, Numinus Founder and CEO. “Numinus Bioscience is demonstrating its leadership in scientific discovery grounded in accessibility, while Numinus Health continues to advance on robust clinic expansion and service delivery targets.We are prepared to sustain this growth trajectory over the coming quarter, and we are grateful to all of our clients, investors, partners and allies for supporting our mission to bring healing and wellness to all.”

“We are proud of our third quarter results that saw a steady increase in revenue from our clinic operations,” said John Fong, Numinus CFO. “As we expand our clinic network and lab activities, we look forward to seeing further revenue growth and operational efficiency across our business units.”

Selected Consolidated Financial Results

For the three months ended May 31, For the nine months ended May 31,
2021 2020 2021 2020
Revenue $562,076 $216,244 $1,022,771 $610,148
Cost of revenue (577,573) (140,650) (1,136,127) (363,879)
(15,497) 75,594 (113,356) 246,269
Operating expenses (4,779,580) (1,231,210) (10,860,168) (4,323,959)
Loss before other items (4,795,077) (1,155,616) (10,973,524) (4,077,690)
Other items (29,347) (2,179,306) (17,509) (2,230,190)
Loss before income tax (4,824,424) (3,334,922) (10,991,033) (6,307,880)
Income tax – 6,187 – (53)
Loss and comprehensive loss $(4,824,424) $(3,328,735) $(10,991,033) $(6,307,933)

 

Numinus’ condensed consolidated interim financial statements for the period ended May 31, 2021 and related management’s discussion and analysis are available on Numinus’ website at www.numinuswellness.com  and under the Company’s profile on SEDAR at www.sedar.com.

###

About Numinus

Numinus Wellness (TSX-V: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinuswellness.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For further information:

John Fong

Chief Financial Officer and Corporate Secretary

Numinus

invest@numinus.ca

May Lee

Communications Manager

Numinus

may@numinus.ca

Posted on

Dr. Sagar Parikh, MD Appointed To NeonMind Specialty Clinics Advisory Board

Vancouver, B.C. – July 28, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FFE: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today the appointment of Dr. Sagar Parikh, MD to its Specialty Clinics Advisory Board. In this role, Dr. Parikh will leverage his vast expertise in clinical treatment and interventional psychiatry including effectively treating patients with psychedelics such as ketamine, esketamine, and neurostimulation for mood and anxiety disorders to guide NeonMind as it develops specialty clinic services for communities in need.

Dr. Parikh has served as the John F. Greden Professor of Depression and Clinical Neuroscience, and Professor of Psychiatry, at the University of Michigan, Ann Arbor since 2015, where he was also designated Associate Director of the Michigan Comprehensive Depression Center. He is an adjunct Professor of Psychiatry at the University of Toronto, where he was on staff full-time from 1994-2015. He serves as the Medical Director at the National Network of Depression Centers, completed two terms as Deputy Psychiatrist-in-Chief at Toronto’s major hospital grouping, the University Health Network, and was head of the Bipolar Clinic and Director of CME at the Centre for Addiction and Mental Health (CAMH) in Toronto.

“Dr. Parikh brings unmatched experience to guide the development and integration of the most effective and cutting-edge protocols and treatment modalities for our expected specialty clinic rollout. We are committed to ensuring that every patient receives tailored, personalized care and each clinic is designed to meet needs of the local community where it will be located. Dr. Parikh’s expert leadership will ensure that we offer best-in-class medical services and programs to every patient,” said Robert Tessarolo, President & CEO of NeonMind.

On his appointment, Dr. Parikh said, “NeonMind is developing a network of clinics that is truly unique in its specialization and breadth of treatment offerings. As mental health care continues to evolve at a rapid pace with new treatments and protocols, NeonMind will be well positioned to have the programs, infrastructure, and education in place to safely and effectively administer these treatments.”

Dr. Sagar Parikh is the author/editor of three books and over 200 peer-reviewed articles and book chapters, and co-author of CANMAT treatment guidelines for Depression and for Bipolar Disorder, the world’s most cited mood disorder guidelines. He holds research grants from multiple funding agencies, covering studies in clinical treatments in mood disorders, health services research, genetics, epidemiology, and educational research. He has conducted clinical trials looking at the combination of medication and psychotherapy for bipolar disorder and for depression, as well as pharmacotherapy trials in mood disorders.

About NeonMind Biosciences Inc.

NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that currently sells mushroom-infused products to promote health and wellness.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s first drug candidate employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

NeonMind’s consumer division currently sells NeonMind-branded coffee products in the United States and Canada through NeonMind’s direct to consumer e-commerce platform.

For more information on NeonMind, go to www.NeonMindBiosciences.com.

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

 

Media Inquiries:

KCSA Strategic Communications
Annie Graf

neonmind@kcsa.com

Tel: 786-390-2644

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Posted on

DELIC Labs President and CSO Dr. Markus Roggen to Speak at MJBizCon

Dr. Roggen to Address the “Cost of the Status Quo: An Economic Look at Extraction Optimization”, Thursday Oct 21, 2021at 2:00pm PT

Vancouver, British Columbia – July 27, 2021 – DELIC Corp Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced Dr. Markus Roggen, President and CEO of its subsidiary DELIC Labs has been selected as a speaker at MJBizCon 2021. Dr. Roggen will lead a discussion on “Cost of the Status Quo: An Economic Look at Extraction Optimization,” Thursday October 21, 2021 at 2:00pm PT. DELIC Labs is a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. DELIC Labs serves as the engine for the DELIC platform, conducting research and developing innovative product lines and intellectual property (IP), including psilocybin vaporization technology for future distribution across the Company’s physical footprint and licensed psychedelic wellness clinics in the United States.

“Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs,” said Dr. Roggen, DELIC Labs President and CSO. “The major obstacle to realize profits from an extraction operation is the disconnect between the business and production teams. Cannabis extraction should not be viewed as a black art but a quantifiable scientific process. And modern process analytics will improve the production and profits.”

Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis, DELIC Labs supports the psychedelic industry with high precision chemical analytics,  metabolomic identification and process optimization. DELIC Labs is one of a handful of licensed psilocybin research labs in Canada and has an aggressive plan to build out a suite of novel compounds and delivery methods for the industry. DELIC Labs is also a leading cannabis analytical and research company boasting clients that include some of the largest brands in the world. DELIC Labs is applying for a Dealer’s License, and intends to eventually commercialize its psilocybin research and associated intellectual property (IP).

Dr. Markus Roggen is President and Chief Scientific Officer of Delic Labs, a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Delic Labs is one of a handful of research labs licensed for both cannabis and psilocybin in Canada. Delic Labs was initially founded as Complex Biotech Discovery Ventures by Dr. Roggen and Prof. Dr. Glenn Sammis in 2018, and rebranded after the sale to Delic Corp. Dr. Roggen received his M/Sci degree from Imperial College, London, UK in 2008. He then pursued his graduate degree in organic chemistry at the Federal Institute of Technology in Zürich (ETHZ), where he received his PhD in 2012. Dr. Roggen was awarded an DAAD postdoctoral fellowship to pursue further training in physical organic chemistry at The Scripps Research Institute in La Jolla in 2013-2014. He then entered the cannabis industry in 2014 and since has held executive positions in analytical and production companies. His research into process optimization and analytical methods has been recognized with a number of awards, ElSohley Award of the ACS, Cannabis Scientist Power List 2020 & 2021, 40 under 40 by Marijuana Venture Magazine among others. Dr. Roggen is also a trusted advisor and mentor to multiple startups, startup accelerators and organizations

About DELIC Labs (formerly Complex Biotech Discovery Ventures Ltd.)

DELIC Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, DELIC Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the DELIC Corp family, the leading psychedelic wellness platform, DELIC Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.

About DELIC Corp, Inc.

DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

Investor Relations Contact

Daniel Southan-Dwyer

Corporate Development

dsd@deliccorp.com

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, information concerning listing on the Canadian Securities Exchange, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Among the key factors that could cause actual ‎results to differ materially from those projected in the ‎forward-looking information and statements are the ‎following: the ability to consummate the Proposed Transaction; ‎the ability to ‎obtain requisite regulatory and securityholder approvals and the satisfaction of ‎other conditions to the ‎consummation of the Proposed Transaction on the proposed terms and schedule; the ability to ‎satisfy the ‎conditions to the conversion of the Subscription ‎‎Receipts (as defined in the Previous Press Release); the potential impact of the announcement or consummation of the Proposed Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Proposed Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN UNITED STATES

Posted on

HAVN LIFE SIGNS AGREEMENT TO ENABLE EXPORT OF PSILOCYBIN INTO CANADA, THE US AND EUROPE

The Agreement with P.A. Benjamin Manufacturing Company whom operates a GMP compliant facility in Jamaica

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”)a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is thrilled to announced a new agreement with P.A. Benjamin Manufacturing Company (“PAB”), a pharmaceutical manufacturing company based in Kingston, Jamaica.

PAB operates a GMP compliant facility and will be contract packing HAVN Life naturally-derived psilocybin, following the necessary protocols to allow for export from Jamaica and import into Canada, the US and Europe. Along with HAVN Life’s collaboration with Hypha Wellness, a Jamaican food and psychoactive mushroom producer, this agreement further reinforces the Company’s commitment to collaboration and long-term industry growth in Jamaica. Further building out this psychedelic supply chain puts HAVN Life in an excellent position to be an early mover, as markets begin to open up around the globe. The agreement will also open the door for HAVN Life to seek API designations, as well as secure further supply agreements with companies seeking high-quality and naturally derived psilocybin.

“As a new industry it is critical that there is stakeholder partnership and as such the partnership between Jamaican GMP manufacturer, P.A. Benjamins, Hypha Wellness, and HAVN Life Sciences is a step in the right direction” remarks Hon. Floyd Green, MP, Minister of Agriculture and Fisheries. “The sustainability of the industry will depend largely on our ability to effectively research psilocybin mushrooms and to combine Agriculture with manufacturing,” he adds.

“This partnership with PAB is absolutely key for our ability to supply safe, quality-controlled psilocybin API’s to researchers and patients around the globe,” says HAVN Life CEO, Tim Moore. “The agreement will make HAVN Life the first company in the Caribbean Community and Common Market with GMP capabilities for psilocybin—a huge step towards our goal to be at the forefront of the international psychedelic supply chain framework,” he adds.

“We’re excited and committed to work with HAVN Life Science and Hypha Wellness to export psilocybin, and build our research and development partnerships,” says Christopher Powell, Director at P.A. Benjamin Manufacturing Company.

“Working with Jamaican stakeholders and the GMP manufacturer P.A. Benjamin’s, we’re focused on developing a framework for manufacturing and exports,” says Benjamin Graeme, Founder, Director at Hypha Wellness. “It’s an exciting time as Jamaica has a unique value position in the international market, and the means to supply it,” he adds.

The agreement and packaging of psilocybin through PAB’s GMP compliant facility will be in compliance with Health Canada and local guidelines.

About HAVN Life Sciences Inc.

HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.

About P.A. Benjamin Manufacturing Company

The Benjamin Family has been a trusted name in Jamaica for over a century, established in 1879. ISO certified, the mission of P.A. Benjamin Manufacturing Company Limited is to manufacture and distribute the highest quality goods in the health care, toiletries, personal care and culinary preparations categories in both the domestic and export markets.

Increased emphasis has been placed on the export potential for its products. Benjamins has embarked on a very aggressive new products development program to complement several of the already established products, and also to venture into new product areas in synergy with the company’s capabilities. The new product development efforts are ongoing with emphasis being placed on the expansion of the pharmaceutical range of products.

Connect

Investor Relations
ir@havnlife.com
(604) 687-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife

Media Contact
savi@emergence-creative.com
(647) 896-8078

Posted on

OPTIMI HEALTH STRENGTHENS CLINICAL AND REGULATORY EXPERTISE

VANCOUVER, BC ( July 27, 2021) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), as part of its strategic aim to fully investigate the science of mushrooms, is pleased to announce the engagement of industry veteran Mr. John Simon to facilitate regulatory submissions and planning relevant to key elements of psychedelic research.

Mr. Simon specializes in gaining site and product licences and related commercialization pathway development efforts. He has served in a variety of managerial and consulting roles overseeing quality assurance and regulatory affairs with direct involvement with the FDA and Health Canada audits relevant to medical device manufacturing, drug manufacturing and testing, drug and device establishments and clinical trial site implementation.

Mr. Simon stated, “Working on the Optimi project is an exciting opportunity to help people with unmet medical needs. The IMPACT team is aiming for a clinical trial that meets international standards and this is the sort of goal I find compelling. I believe our studies will offer an extraordinary opportunity to identify the beneficial differences between systemic and natural formulations, and the FDA’s botanical guide/framework could offer strategic insights as to how Optimi can achieve intellectual property (IP) rights even while executing the clinical trial. I have worked in drug development before, and one project in particular went on to become the largest biotech licensing deal in Canadian history at that time. I am keenly aware that mental health & overall wellness is an immense field of opportunity and look forward to helping unlock the potential of psychedelics.

A long-time resident of Edmonton, Canada, he was the very first cannabis sector license holder in that city which he later sold to Avant Brands. He was instrumental in assisting Aurora Cannabis Inc. as well as Radient Technologies in the implementation of Quality Management Systems (QMS) regarding key commercial activities.  He has built an extensive client base in the region including a major chocolatier’s cannabis infusion goals. He has undertaken research & development efforts for globally recognized non-cannabis health & wellness clients in the treatment of common colds, skin beautification, sunscreens, and conditioners. His clinical trial experience includes advanced studies for therapeutic cancer vaccines, as well as numerous projects supporting clinical trials for drugs, natural health products and medical devices.

Organizationally, Mr. Simon serves under the auspices of Optimi’s service agreement with the IMPACT Clinical Trial Accelerator Program of Alberta’s Life Sciences Innovation Hub at the University of Calgary. The IMPACT program provides Optimi expert clinical support towards commercializing proposed psilocybin-based formulations through the conduct of clinical trials and expert assistance towards securing regulatory approval. John Simon B.Sc., RAC, CQA, RQAP-GLP earned his B.Sc. from the University of Alberta, is a Senior Member of the American Society for Quality, is a Certified Quality Auditor (CQA) through the American Society for Quality and holds Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society and RQAP-GLP certification through the Society of Quality Assurance.

JJ Wilson, Optimi Board Chair, notes, “We were very pleased when the IMPACT team presented John as the expert to assist in managing our path through these particularly critical aspects of our strategic plan. To credibly work towards a successful commercial future for psychedelics, we have to align our efforts to meet the standards of both the FDA and Health Canada. With John’s participation, we have significantly upped our game and ability to participate in a much larger arena. Our ultimate goals are for the betterment of mental health and human optimization around the world, and today is an important step forward in meeting that expectation.”

On Behalf of the Board of Directors,

Optimi Health Corp.

Mike Stier
President, Chief Executive Officer and Director

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the Company’s potential Nasdaq listing, the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.